Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA: Bad Lead Test Results Tied To Test-Tube Stopper Chemical

Executive Summary

An investigation by FDA and BD has concluded that a chemical used in some test-tube stoppers is the reason for false results on some blood-based lead tests from Magellan Diagnostics.

You may also be interested in...

Magellan Lead Test Recall Expanded After First Attempted Fix Found Insufficient

Several additional batches of Magellan’s LeadCare II tests are being recalled as efforts to address the root cause continue.

BD Handed US FDA Warning Letter In Lead-Test Investigation

The agency letter cites quality systems, Medical Device Reporting and device clearance concerns. It stems from an ongoing investigation into lead tests distributed by Magellan Biosciences that sometimes give faulty results.

US FDA, CDC Warn Of False Results On Lead Blood Tests

Common blood tests for lead poisoning manufactured by Magellan Diagnostics could give false low results if used with venous blood, FDA warned. About 8 million of the tests have been performed since 2014.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts